On March 21, 2022 Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, reported the closing of a USD$12M equity financing to enable expansion of Qu’s team, initiation of an additional three Phase 2 clinical studies, and the acceleration of Qu’s novel immunomodulation platform (Press release, Qu Biologics, MAR 21, 2022, View Source [SID1234610479]).
Hal Gunn, MD, CEO of Qu Biologics, stated, "Our team is grateful for this new equity funding that will allow us to expand our dedicated team and play an essential role in initiating three new Phase 2 randomized placebo-controlled clinical studies. Two of these important trials are in critical indications for which there are no effective treatments – innate immune decline in the elderly and post-operative innate immune suppression."
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are highly motivated and excited to be in the position to strategically move forward with the expansion of our science, manufacturing, and clinical teams to accelerate the development of Qu’s first-in-class multifaceted immunotherapy platform, which is designed to safely restore and mobilize the essential effector functions of the innate immune system through a process that involves innate immune training and tissue-specific targeting of activated immune cells. In contrast to other immunotherapies that try to target one cell or receptor, SSI therapy harnesses and directs the multiple components of innate immunity required by the body to overcome pathology and heal," said Dr. Shirin Kalyan (PhD), Qu’s VP Scientific Innovation. Dr. Gunn added, "Given the broad application of our SSI platform, this funding brings Qu Biologics one step closer to providing critical, game-changing treatments for people living with cancer, infections, and chronic inflammatory diseases."
For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com.